GeneDx Holdings (WGS) Liabilities and Shareholders Equity (2020 - 2025)
GeneDx Holdings (WGS) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $523.7 million as the latest value for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 24.88% to $523.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $987.6 million, a 17.91% decrease, with the full-year FY2025 number at $523.7 million, up 24.88% from a year prior.
- Liabilities and Shareholders Equity was $523.7 million for Q4 2025 at GeneDx Holdings, up from $463.9 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $933.3 million in Q2 2022 to a low of $175.5 million in Q2 2021.
- A 5-year average of $492.4 million and a median of $476.4 million in 2023 define the central range for Liabilities and Shareholders Equity.
- Peak YoY movement for Liabilities and Shareholders Equity: soared 431.68% in 2022, then crashed 49.66% in 2023.
- GeneDx Holdings' Liabilities and Shareholders Equity stood at $554.1 million in 2021, then fell by 11.4% to $490.9 million in 2022, then decreased by 14.7% to $418.8 million in 2023, then increased by 0.15% to $419.4 million in 2024, then rose by 24.88% to $523.7 million in 2025.
- Per Business Quant, the three most recent readings for WGS's Liabilities and Shareholders Equity are $523.7 million (Q4 2025), $463.9 million (Q2 2025), and $419.4 million (Q4 2024).